Return to content in this issue
A Pilot Experience Using a 1-Bag Intravenous Rapid Desensitization Protocol for Chemotherapy and Biologics in a Cohort of Patients With Access to a Delabeling Pathway
Vázquez-Revuelta P1,2,3, Lleonart-Bellfill R1,2,3, Molina-Mata K1,4, Muñoz-Sánchez C1,5, Rey-Salido M1,5, Madrigal-Burgaleta R1,6
1Drug Desensitisation Centre, Catalan Institute of Oncology (Institut Català d’Oncologia – ICO), Barcelona, Spain
2Allergy Department, Hospital Universitari de Bellvitge, Barcelona, Spain
3Institut d’Investigació Biomèdica de Bellvitge ‐ IDIBELL, Barcelona, Spain
4Medical Oncology Department, Catalan Institute of Oncology (Institut Català d’Oncologia – ICO), Barcelona, Spain
5Pharmacy Department, Catalan Institute of Oncology (Institut Català d’Oncologia – ICO), Barcelona, Spain
6Allergy & Severe Asthma Service, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK
J Investig Allergol Clin Immunol 2023; Vol 33(4)
: 289-291
doi: 10.18176/jiaci.0860
Key words: Drug allergy, Delabeling, Drug challenge, Desensitization, Personalized medicine
| Title | Type | Size | |
|---|---|---|---|
 |
doi10.18176_jiaci.0860_supplemental-materials-figure_1.pdf | 305.74 Kb | |
|
doi10.18176_jiaci.0860_supplemental-materials-table_1.pdf | 214.60 Kb |
